Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?
Axsome sees at least $8 billion in potential peak Auvelity sales. Additional drugs and pipeline candidates could fuel long-term growth.
AXSM - Axsome Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$283.00
DETAILS
HIGH:
$380.00
LOW:
$246.00
MEDIAN:
$275.00
CONSENSUS:
$283.00
UPSIDE:
80.09%
Stock News
4 CNS Drug Stocks Worth Watching This World Mental Health Day
AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?
Axsome Therapeutics is seeing massive revenue growth as it expands its footprint in the central nervous system treatment market. Moderna is moving beyond its pandemic roots by advancing a deep pipeline of mRNA-based vaccines and oncology therapies.
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2026 on Monday, November 2, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Axsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for central nervous system disorders. Vertex Pharmaceuticals remains a highly profitable giant with absolute dominance in cystic fibrosis and expanding reach in gene therapy.
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer's Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer's Day
The Shared Goals: Navigating Alzheimer's Agitation survey finds that Alzheimer's disease agitation is often only recognized after daily life is significantly disrupted Ninety-seven percent of care partners reported that agitation negatively impacted their loved one's quality of life, and three in four wish they had recognized symptoms sooner Results from the survey were recently presented at Psych Congress 2026 in New Orleans, Louisiana Survey conducted by The Harris Poll and in collaboration with CaringKind NEW YORK, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today, in connection with World Alzheimer's Day, announced results of the Shared Goals: Navigating Alzheimer's Agitation survey that highlight the profound impact that symptoms of agitation can have on people with Alzheimer's disease and their family care partners.
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction
Axsome Therapeutics (NASDAQ: AXSM) executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in Alzheimer's disease agitation, while management expects operating expenses to remain relatively stable in the second half of the year. Speaking at Morgan Stanley's Global Healthcare Conference, Chief Financial Officer
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference
Axsome Therapeutics (NASDAQ: AXSM) executives highlighted growth across its commercial portfolio, an expanded sales force and multiple late-stage clinical programs during the H.C. Wainwright 28th Annual Global Investment Conference. Chief Operating Officer Mark Jacobson said the company has three marketed products: Auvelity for major depressive disorder and Alzheimer's disease agitation; Sunosi for excessive daytime sleepiness associated
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer's Launch Gains Traction
Axsome Therapeutics NASDAQ: AXSM executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in Alzheimer's disease agitation, while management expects operating expenses to remain relatively stable in the second half of the year.
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference
Axsome Therapeutics NASDAQ: AXSM executives highlighted growth across its commercial portfolio, an expanded sales force and multiple late-stage clinical programs during the H.C. Wainwright 28th Annual Global Investment Conference.
Bank of America Corp DE Acquires Shares of 452,491 Axsome Therapeutics, Inc. $AXSM
Bank of America Corp DE bought a new stake in Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 452,491 shares of the company's stock, valued at approximately $110,756,000. Bank of America Corp DE owned approximately
Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?
Axsome Therapeutics' revenue is growing at a good clip. The company has a deep pipeline as well.
Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Axsome Therapeutics is seeing significant revenue growth as its central nervous system portfolio gains commercial traction. Moderna is transitioning its mRNA platform toward a broader array of respiratory and oncology treatments to offset declining COVID-19 vaccine sales.
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Axsome Therapeutics is generating rapid revenue growth through its expanding portfolio of commercialized central nervous system treatments. Revolution Medicines is advancing a high-potential pipeline of RAS(ON) inhibitors aimed at treating some of the most difficult cancers.
Is Axsome Therapeutics a Buy on the Dip?
Axsome Therapeutics has launched exciting new drugs over the past year, and they are delivering growth. The biopharma player's late-stage pipeline could translate into additional products over the next few years.
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data in major depressive disorder and Alzheimer's disease agitation and eight additional encore data posters spanning its psychiatry and neurology portfolio at Psych Congress 2026, being held September 15-19, in New Orleans, Louisiana.
Axsome Therapeutics, Inc. (AXSM) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.
Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Price Targets
Axsome Therapeutics price target lowered to $295 from $297 at RBC Capital
$295.00
(was $168.60)
RBC Capital
Axsome Therapeutics price target lowered to $267 from $280 at Deutsche Bank
$267.00
(was $188.66)
Deutsche Bank
Axsome Therapeutics price target lowered to $247 from $251 at Morgan Stanley
$247.00
(was $198.57)
Morgan Stanley
Truist Securities Starts Axsome Therapeutics (AXSM) at Buy
$285.00
(was $203.10)
Srikripa Devarakonda
·
Truist Financial
Axsome Therapeutics (AXSM) PT Raised to $316 at Mizuho
$316.00
(was $215.77)
Graig Suvannavejh
·
Mizuho Securities
Axsome Therapeutics price target lowered to $297 from $304 at RBC Capital
$297.00
(was $219.00)
Leonid Timashev
·
RBC Capital
Axsome Therapeutics price target raised to $251 from $242 at Morgan Stanley
$251.00
(was $221.21)
Morgan Stanley
Axsome Therapeutics (AXSM) PT Raised to $268 at Needham
$268.00
(was $220.89)
Ami Fadia
·
Needham
Axsome Therapeutics price target raised to $275 from $260 at Guggenheim
$275.00
(was $220.89)
Guggenheim
Axsome Therapeutics price target raised to $256 from $255 at Wells Fargo
$256.00
(was $220.89)
Wells Fargo
Axsome Therapeutics initiated with an Outperform at BMO Capital
$310.00
(was $221.64)
Malcolm Hoffman
·
BMO Capital
Axsome Therapeutics price target raised to $304 from $302 at RBC Capital
$304.00
(was $242.60)
Leonid Timashev
·
RBC Capital
Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
$380.00
(was $246.34)
Andrew Tsai
·
Jefferies
Axsome Therapeutics price target lowered to $280 from $281 at Deutsche Bank
$280.00
(was $230.10)
David Hoang
·
Deutsche Bank
Axsome Therapeutics price target raised to $242 from $217 at Morgan Stanley
$242.00
(was $230.11)
Morgan Stanley
Axsome Therapeutics price target raised to $267 from $255 at Needham
$267.00
(was $230.63)
Needham
Axsome Therapeutics price target raised to $302 from $242 at RBC Capital
$302.00
(was $231.00)
Leonid Timashev
·
RBC Capital
Axsome Therapeutics price target raised to $246 from $241 at Baird
$246.00
(was $223.70)
Brian Skorney
·
Robert W. Baird
Axsome Therapeutics price target raised to $290 from $270 at H.C. Wainwright
$290.00
(was $223.70)
H.C. Wainwright
Axsome Therapeutics price target raised to $280 from $250 at Oppenheimer
$280.00
(was $223.34)
Oppenheimer